Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GLS | O94925 | 6/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12890589 | 0.85 | GLS (0.43) | NPC1RAB9AMEN1KMT2AGLS | |
| SCHEMBL1244267 | 0.85 | GLS (0.43) | NPC1RAB9AMEN1KMT2AGLS | |
| SCHEMBL2685328 | 0.80 | GPR142 (0.60) | KDM4EGPR142 | |
| SCHEMBL2685334 | 0.80 | GPR142 (0.60) | KDM4EGPR142 | |
| SCHEMBL4949871 | 0.79 | HDAC6 (0.66) | NPC1RAB9A | |
| SCHEMBL21225987 | 0.79 | HDAC6 (0.66) | NPC1RAB9A | |
| SCHEMBL4950599 | 0.79 | SMN1; SMN2 (0.62) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL21225986 | 0.79 | HDAC6 (0.66) | NPC1RAB9A | |
| SCHEMBL4951239 | 0.78 | CCNE1 (0.53) | GPR142 | |
| SCHEMBL4949381 | 0.78 | CCNE1 (0.60) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | REMPEX PHARMACEUTICALS, INC. | 2008-03-27 | — | — | US | disclosed |
| EP-1758920-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | REMPEX PHARMACEUTICALS, INC. | 2006-01-05 | — | — | US | disclosed |
| WO-2005113579-A1 | BACTERIAL EFFLUX PUMP INHIBITORS AND METHODS OF TREATING BACTERIAL INFECTIONS | MPEX PHARMACEUTICALS, INC. (US) | 2005-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076741-A1 | ENHANCEMENT OF TIGECYCLINE POTENCY USING EFFLUX PUMP INHIBITORS | ABCB1, ABCB11, SLC47A2 | NPC1 503/4885RAB9A 534/4885MEN1 4742/4885 |
| US-20060003944-A1 | Bacterial efflux pump inhibitors and methods of treating bacterial infections | ABCB11, ABCB1, ABCC1 | NPC1 97/4885RAB9A 463/4885MEN1 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.